A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 335 participants.

Also called NCT02453685

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 335 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02453685
  • EudraCT 2014-003708-62
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Bulgaria, Hungary, India, Serbia, South Korea, Thailand, Türkiye, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02453685. Randomized; no masking; primary purpose treatment. Start 2015-08-31 (actual); primary completion 2016-09-20 (actual). Results posted on 2019-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
biphasic insulin aspart 30
Intervention (Drug)
insulin glargine
Intervention (Drug)
insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02453685
Content hash
5e9d2a871f8b0c6ba9e5963f16478fabab74d460ca0de5a8b9cb61821222f470